Study on the improvement of high-fat/high-fructose diet-induced nonalcoholic fatty liver disease by mycelium glycoprotein (Antrodan) of Antrodia cinnamomea

Autor: Zhang, Wen-Juan, 張文娟
Rok vydání: 2019
Druh dokumentu: 學位論文 ; thesis
Popis: 107
Obesity is one of the important factors to cause the nonalcoholic fatty liver disease (NAFLD), and increasing trends in the prevalence of NAFLD have being resulted from the obesity. The Food and Drug Administration (FDA) currently doesn't have an approved drug for specific treatment of NAFLD, thus seeking the complementary and alternative medicine (CAM) is currently considered as one of the strategies. According to previous reports, the glycoprotein (Antrodan) isolated from the mycelium of Antrodia cinnamomea (ACM) has been indicated with significant anti-inflammatory biological activity, especially for liver protection has been the most interested to people. The aims of this study were to explore the effects of Antrodan in improving the symptoms of NAFLD in mice. NAFLD was induced by high-fat high-fructose diet (HFD) in the male 5-week-old C57BL / 6 mice and was investigated from the oral administration of Antrodan (20 and 40 mg/Kg) in simultaneously compared with the treatment of the weight loss drug Orlistat (10 mg/Kg). The results showed that the HFD diet significantly caused obesity and fatty liver symptoms. In blood biochemical parameters, low dose of Antrodan reduced the triglyceride (TG), blood glucose, uric acid, and liver index (GOT and GPT) by 1.87%, 1.71%, 1.45%, 2% and 1.45 % respectively, and high dose Antrodan reduced the TG, blood glucose, uric acid, GOT and GPT by 2.00%, 1.37%, 1.07%, 1.09 and 1.22% respectively, while regardless of dose in Antrodan reduced the total cholesterol (T-CHO) by 1.16%, compared with the HFD group. In the results of enzyme immunoassay, low doses of Antrodan reduced the insulin by 1.17%, adiponectin by 0.87%, and leptin by 1.30%, and high dose Antrodan reduced insulin by 1.22%, adiponectin by 0.85%, and leptin by 0.28%, compared with HFD group. The expression of the lipid metabolism associated proteins SIRT1, p-AMPK and PGC-1α were up-regulated by 0.94, 0.83 and 1.59% respectively in low dose Antrodan group, while the increasing by 0.84, 0.88 and 1.48%, respectively were shown in high dose Antrodan group. In addition, the expression of PPARr and SREBP1 proteins were down-regulated by 1.04 and 1.09% respectively in low dose Antrodan group. While there were down-regulated by 1.30 and 1.17% respectively in high dose Antrodan group. Oral Antrodan showed the better effects in the expressions of Sirt1, p-AMPK, PPAR, SREBP1 and PGC-1α proteins than those of Orlistat. Overall, it can be concluded that the Antrodan has the partial effects in the improvement of lipid metabolism and accumulation in the liver even at low dosage. The improved effects of Antrodan on NAFLD symptoms were proposed from the regulation of SIRT1/AMPK/PGC-1α pathway, which was reported firstly that the Antrodan isolated from ACM could be one of the candidate of CAM in the improvement of the symptoms of NAFLD. Keywords: nonalcoholic fatty liver disease, Antrodia cinnamomea, glycoprotein, mouse, SIRT1, AMPK
Databáze: Networked Digital Library of Theses & Dissertations
Externí odkaz: